GLycaemic Outcomes With Whey Protein in ageING
About this study
The goal of this placebo-controlled, partial crossover design study is to identify the impact of consuming whey protein before meals on free-living glucose control in older adults living with type 2 diabetes. The primary specific objective is to determine the effect of a thrice daily whey protein pre-meal supplementation at two doses, on glucose excursions over a 7-day free-living period in adults aged 70-90 years of age, living with type 2 diabetes, compared with a non-protein placebo. Participants will consume the whey protein and placebo for 7 days each, before each meal. All participants will consume the placebo and one of two doses of whey protein, in a randomised order.
- Condition
- Type 2 Diabetes
- Tested
- Glycaemic control with whey protein, Glycaemic control with different doses of whey protein
- Sponsor
- University of Birmingham
Who can join
- Age
- 70 to 90 years
- Sex
- All sexes
- Healthy volunteers
- Accepted
Inclusion 12
- Minimum age: 70 years
- Maximum age: 90 years
- Study condition: Type 2 Diabetes
- Male or female
- 70-90 years old
- Type 2 Diabetes (confirmed with glycated haemoglobin (HbA1c) \>6.5% in clinic or in SportExR)
- Stable body mass (body mass index (BMI) ≤40kg/m2)
- Generally healthy, assessed via a General Health Questionnaire (GHQ)
- Some residual beta-cell activity (confirmed with urine test on induction)
- Normal or moderately increased albuminuria (needs to be below 300mg/g)
- Normal, mildly or moderately decreased glomerular filtration rate (GFR) (needs to be above 45ml/min/1.732).
- Able and willing to attend SportExR a total of 5 times: 1 induction and 2 testing visits and 2 return check-up visits.
Exclusion 13
- \<70 years old and over 90 years of age
- Currently on fast-acting insulin therapy (i.e., Humalog)
- Confirmed uncontrolled diabetes (HbA1C \>10% or 85mmol/mol).
- Currently on GLP-1 therapy
- Habitual smoker or vaper
- Veganism
- Lactose or dairy intolerance
- Coeliac or gluten intolerance
- History of gastrointestinal disease
- Experienced a hyperglycaemic or hypoglycaemic event requiring treatment in the past 12 months
- Recent Ischemic stroke (\<3 months).
- Use of anticoagulants (e.g. warfarin, rivaroxaban)
- Considered unwilling or unable to comply with the study protocol requirements by the research team
Where
2 sites, 2 recruiting
Heartlands Hospital
Birmingham, United Kingdom
School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham
Birmingham, West Midlands, United Kingdom
Contact
-
Leigh Breen, PhD
(0)1214144109 l.breen@bham.ac.uk
-
Marie Korzepa, PhD
Potential match only. Final eligibility is determined by the study team.